{"pmid":32296994,"title":"The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments.","text":["The double burden of disease of COVID-19 in cardiovascular patients: overlapping conditions could lead to overlapping treatments.","Eur J Epidemiol","Gonzalez-Jaramillo, Nathalia","Low, Nicola","Franco, Oscar H","32296994"],"journal":"Eur J Epidemiol","authors":["Gonzalez-Jaramillo, Nathalia","Low, Nicola","Franco, Oscar H"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296994","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s10654-020-00628-1","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664266651291353088,"score":8.233237,"similar":[{"pmid":32056249,"title":"Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV.","text":["Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV.","First reported from Wuhan, The People's Republic of China, on 31 December 2019, the ongoing outbreak of a novel coronavirus (2019-nCoV) causes great global concerns. Based on the advice of the International Health Regulations Emergency Committee and the fact that to date 24 other countries also reported cases, the WHO Director-General declared that the outbreak of 2019-nCoV constitutes a Public Health Emergency of International Concern on 30 January 2020. Together with the other two highly pathogenic coronaviruses, the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), 2019-nCov and other yet to be identified coronaviruses pose a global threat to public health. In this mini-review, we provide a brief introduction to the pathology and pathogenesis of SARS-CoV and MERS-CoV and extrapolate this knowledge to the newly identified 2019-nCoV.","J Med Virol","Liu, Jia","Zheng, Xin","Tong, Qiaoxia","Li, Wei","Wang, Baoju","Sutter, Kathrin","Trilling, Mirko","Lu, Mengji","Dittmer, Ulf","Yang, Dongliang","32056249"],"abstract":["First reported from Wuhan, The People's Republic of China, on 31 December 2019, the ongoing outbreak of a novel coronavirus (2019-nCoV) causes great global concerns. Based on the advice of the International Health Regulations Emergency Committee and the fact that to date 24 other countries also reported cases, the WHO Director-General declared that the outbreak of 2019-nCoV constitutes a Public Health Emergency of International Concern on 30 January 2020. Together with the other two highly pathogenic coronaviruses, the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), 2019-nCov and other yet to be identified coronaviruses pose a global threat to public health. In this mini-review, we provide a brief introduction to the pathology and pathogenesis of SARS-CoV and MERS-CoV and extrapolate this knowledge to the newly identified 2019-nCoV."],"journal":"J Med Virol","authors":["Liu, Jia","Zheng, Xin","Tong, Qiaoxia","Li, Wei","Wang, Baoju","Sutter, Kathrin","Trilling, Mirko","Lu, Mengji","Dittmer, Ulf","Yang, Dongliang"],"date":"2020-02-15T11:00:00Z","year":2020,"_id":"32056249","week":"20207|Feb 10 - Feb 16","doi":"10.1002/jmv.25709","keywords":["*coronavirus","*immnopathology","*immune responses","*pathogenesis","*respiratory tract","*virus classification"],"source":"PubMed","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1663352134658162688,"score":99.10217},{"pmid":32248966,"title":"The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.","text":["The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease.","Coronavirus disease 2019 (COVID-19), caused by a novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in a cluster of patients presenting with pneumonia symptoms in Wuhan, China, in December of 2019. Over the past few months, COVID-19 has developed into a worldwide pandemic, with over 400,000 documented cases globally as of March 24, 2020. The SARS-CoV-2 virus is most likely of zoonotic origin, but has been shown to have effective human-to-human transmission. COVID-19 results in mild symptoms in the majority of infected patients, but can cause severe lung injury, cardiac injury, and death. Given the novel nature of COVID-19, no established treatment beyond supportive care exists currently, but extensive public-health measures to reduce person-to-person transmission of COVID-19 have been implemented globally to curb the spread of disease, reduce the burden on healthcare systems, and protect vulnerable populations, including the elderly and those with underlying medical comorbidities. Since this is an emerging infectious disease, there is, as of yet, limited data on the effects of this infection on patients with cardiovascular disease, particularly so for those with congenital heart disease. We summarize herewith the early experience with COVID-19 and consider the potential applicability to and implications for patients with cardiovascular disease in general and congenital heart disease in particular.","Int J Cardiol","Tan, Weiyi","Aboulhosn, Jamil","32248966"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by a novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in a cluster of patients presenting with pneumonia symptoms in Wuhan, China, in December of 2019. Over the past few months, COVID-19 has developed into a worldwide pandemic, with over 400,000 documented cases globally as of March 24, 2020. The SARS-CoV-2 virus is most likely of zoonotic origin, but has been shown to have effective human-to-human transmission. COVID-19 results in mild symptoms in the majority of infected patients, but can cause severe lung injury, cardiac injury, and death. Given the novel nature of COVID-19, no established treatment beyond supportive care exists currently, but extensive public-health measures to reduce person-to-person transmission of COVID-19 have been implemented globally to curb the spread of disease, reduce the burden on healthcare systems, and protect vulnerable populations, including the elderly and those with underlying medical comorbidities. Since this is an emerging infectious disease, there is, as of yet, limited data on the effects of this infection on patients with cardiovascular disease, particularly so for those with congenital heart disease. We summarize herewith the early experience with COVID-19 and consider the potential applicability to and implications for patients with cardiovascular disease in general and congenital heart disease in particular."],"journal":"Int J Cardiol","authors":["Tan, Weiyi","Aboulhosn, Jamil"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32248966","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijcard.2020.03.063","source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Prevention","Treatment"],"weight":1,"_version_":1663352136199569409,"score":90.33971},{"pmid":32220278,"title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","text":["Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","Lancet","Ritchie, Andrew I","Singanayagam, Aran","32220278"],"journal":"Lancet","authors":["Ritchie, Andrew I","Singanayagam, Aran"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220278","week":"202014|Mar 30 - Apr 05","doi":"10.1016/S0140-6736(20)30691-7","link_comment_for":"32192578","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135138410497,"score":78.14409},{"pmid":32266501,"title":"Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19.","text":["Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19.","AIDS Behav","Carrico, Adam W","Horvath, Keith J","Grov, Christian","Moskowitz, Judith T","Pahwa, Savita","Pallikkuth, Suresh","Hirshfield, Sabina","32266501"],"journal":"AIDS Behav","authors":["Carrico, Adam W","Horvath, Keith J","Grov, Christian","Moskowitz, Judith T","Pahwa, Savita","Pallikkuth, Suresh","Hirshfield, Sabina"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266501","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s10461-020-02854-w","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Methamphetamine"],"_version_":1663609715789135874,"score":73.58133},{"pmid":32292919,"pmcid":"PMC7151392","title":"The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer.","text":["The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer.","JACC CardioOncol","Ganatra, Sarju","Hammond, Sarah P","Nohria, Anju","32292919"],"journal":"JACC CardioOncol","authors":["Ganatra, Sarju","Hammond, Sarah P","Nohria, Anju"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292919","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaccao.2020.03.001","keywords":["ACE-2, angiotensin-converting enzyme 2","ACEi, Angiotensin converting enzyme inhibitor","ARB, Angiotensin receptor blocker","CDC, Centers for Disease Control","COVID-19","CVD, Cardiovascular disease","Coronavirus","Coronavirus disease 2019, COVID-19","MERS-CoV, Middle East respiratory syndrome coronavirus","SARS-CoV-2","SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2","WHO, World Health Organization","cancer","cardio-oncology","cardiovascular disease"],"source":"PubMed","topics":["Treatment","Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1664266295566139392,"score":62.39892}]}